Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes.

نویسندگان

  • Sylvia T Singer
  • Elliott P Vichinsky
  • Nancy Sweeters
  • Eliezer Rachmilewitz
چکیده

Alter, B.P. (2003) Cancer in Fanconi anemia, 1927– 2001. Cancer, 97, 425–440. Baron, F., Sybert, V.P. & Andrews, R.G. (1989) Cutaneous and extracutaneous neutrophilic infiltrates (Sweet syndrome) in three patients with Fanconi anemia. Journal of Pediatrics, 115, 726–729. Briot, D., Mace-Aime, G., Subra, F. & Rosselli, F. (2008) Aberrant activation of stress-response pathways leads to TNF-alpha oversecretion in Fanconi anemia. Blood, 111, 1913–1923. Buck, T., Gonzalez, L.M., Lambert, W.C. & Schwartz, R.A. (2008) Sweet’s syndrome with hematologic disorders: a review and reappraisal. International Journal of Dermatology, 47, 775–782. Chatham-Stephens, K., Devere, T., Guzman-Cottrill, J. & Kurre, P. (2008) Metachronous manifestations of Sweet’s syndrome in a neutropenic patient with Fanconi anemia. Pediatric Blood & Cancer, 51, 128–130. Guhl, G. & Garcia-Diez, A. (2008) Subcutaneous sweet syndrome. Dermatologic Clinics, 26, 541–551. viii–ix. Hospach, T., von den Driesch, P. & Dannecker, G.E. (2009) Acute febrile neutrophilic dermatosis (Sweet’s syndrome) in childhood and adolescence: two new patients and review of the literature on associated diseases. European Journal of Pediatrics, 168, 1–9. McDermott, M.B., Corbally, M.T. & O’ Marcaigh, A.S. (2001) Extracutaneous Sweet syndrome involving the gastrointestinal tract in a patient with Fanconi anemia. Journal of Pediatric Hematology/oncology, 23, 59–62. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937–951. Vignon-Pennamen, M.D., Juillard, C., Rybojad, M., Wallach, D., Daniel, M.T., Morel, P., Verola, O. & Janin, A. (2006) Chronic recurrent lymphocytic Sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases. Archives of Dermatology, 142, 1170–1176.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

BACKGROUND Several studies with erythropoiesis-stimulating agents claim that maintenance therapy of renal anaemia may be possible at extended dosing intervals; however, few studies were randomized, results varied, and comparisons between agents were absent. We report results of a multi-national, randomized, prospective trial comparing haemoglobin maintenance with methoxy polyethylene glycol-epo...

متن کامل

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

Patients with myelodysplastic syndromes (MDS) often develop anaemia resulting in frequent transfusions and fatigue. Darbepoetin alfa is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anaemia. This single-arm, phase 2 study examined the efficacy of darbepoetin alfa 500 microg every 3 weeks (Q3W) for treating anaemia in low-risk MDS patients (after 6 weeks, p...

متن کامل

Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).

BACKGROUND Darbepoetin alfa is an erythropoietic agent with a 3-fold longer elimination half-life than recombinant human erythropoietin (rHuEpo), which allows less frequent dosing. This study investigated the safety and efficacy of darbepoetin alfa for treating anaemia in dialysis patients, using a dosing regimen that was independent of the patient's body weight (unit dosing). METHODS Dialysi...

متن کامل

Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.

BACKGROUND Anaemia is aggravated by the coexistence of chronic kidney disease (CKD) in patients infected with human immunodeficiency virus (HIV). Darbepoetin alfa effectively alleviates CKD-associated anaemia with less frequent dosing than recombinant human erythropoietin (EPO). The current study aimed to determine the efficacy, safety and cost-effectiveness of darbepoetin alfa compared with er...

متن کامل

A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis

Background. Erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and beta, and darbepoetin alfa have improved the management of anaemia secondary to chronic kidney disease. Numerous studies have reported a dose reduction when patients receiving dialysis were converted from epoetin to darbepoetin alfa using the starting dose conversion of 200:1 as indicated on the prescribing label by t...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • British journal of haematology

دوره 154 2  شماره 

صفحات  -

تاریخ انتشار 2011